Search Results for "cancer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cancer. Results 361 to 370 of 601 total matches.
A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
can cause cirrhosis and hepatic
cancer. Universal childhood vaccination against HBV,
introduced ...
The FDA has approved a two-dose hepatitis B virus
(HBV) vaccine (Heplisav-B – Dynavax) for use in adults
≥18 years old. The three other HBV vaccines marketed
in the US are usually administered in 3 doses. Engerix-B
and Recombivax HB are licensed for use in persons of
all ages. A combination hepatitis A/B vaccine (Twinrix)
contains the same hepatitis B component as Engerix-B
and is licensed for use only in adults.
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
Pregnancy
High risk of arterial or venous thrombotic events1
Current or history of breast cancer ...
The FDA has approved a combination oral
contraceptive containing the estrogen estetrol and the
progestin drospirenone (Nextstellis – Mithra/Mayne).
Estetrol is the first new estrogen to become available
in the US in 50 years. Drospirenone is available alone
(Slynd) and in combinations with the estrogen ethinyl
estradiol for prevention of pregnancy.
Idarubicin
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991 (Issue 852)
Cerubidine idarubicin for AML Cancer chemotherapy Antacids Adriamycin cytarabine daunorubicin doxorubicin ...
Idarubicin hydrochloride (Idamycin - Adria), an anthracycline structurally related to daunorubicin (Cerubidine, and others) and doxorubicin (Adriamycin, and others), was recently approved in the USA for treatment of acute myelogenous leukemia (AML) in adults.
Nutritional Support for Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010 (Issue 1344)
of lung
cancer in smokers, and adding omega-3 fatty acids.
CONCLUSION — The results of the first AREDS ...
An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new product] builds on the original PreserVision Eye Vitamin AREDS Formula, the only formula proven to slow the progression of moderate-to-advanced AMD.”
Bisphosphonates - Duration of Use Revisited
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
, atypical fractures of the
femur, and possibly esophageal cancer.1,2 So for how
long should patients take ...
Long-term use of bisphosphonates for prevention and
treatment of osteoporosis has been associated with
osteonecrosis of the jaw, atypical fractures of the
femur, and possibly esophageal cancer. So for how
long should patients take them?
Extracorporeal Photochemotherapy for Cutaneous T-cell Lymphoma
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988 (Issue 776)
IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
Cancer chemotherapy cutaneous T-cell lymphoma ...
Photopheresis is a new technique recently approved by the US Food and Drug Administration for treatment of cutaneous T-cell lymphoma. It combines oral administration of a photoactivatable cytotoxic drug with leukapheresis and extracorporeal exposure of leukocytes to long-wave ultraviolet light (UVA). This procedure requires use of a 'UVAR Instrument' manufactured by Therakos, a subdivision of Johnson and Johnson.
Balloon Dilatation Of The Prostate
The Medical Letter on Drugs and Therapeutics • Jun 29, 1990 (Issue 821)
the possibility of diagnosing an occult cancer. Patients undergoing balloon dilatation may require a needle biopsy ...
To avoid the morbidity and occasional mortality of transurethral resection or open prostatectomy, some urologists are now using balloon dilatation of the prostatic urethra to treat benign prostatic hypertrophy.
Gonadorelin For Induction Of Ovulation
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990 (Issue 823)
(Medical
Letter, 25:106, 1983). Analogs of GnRH have been used to treat endometriosis and advanced cancer ...
Gonadorelin (goe nad oh rell'; in) acetate (Lutrepulse - Ortho), a synthetic decapeptide identical in amino acid sequence to human gonadotropin-releasing hormone (GnRH), was recently approved by the US Food and Drug Administration for treatment of primary hypothalamic amenorrhea. Gonadorelin hydrochloride (Factrel) was previously available for diagnostic use (Medical Letter, 25:106, 1983). Analogs of GnRH have been used to treat endometriosis and advanced cancer of the prostate (Medical Letter, 27:71, 1985).
Turmeric Supplements
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
effects7 and anti-cancer properties,
including induction of apoptosis.8
ADVERSE EFFECTS — Turmeric ...
Turmeric is a spice derived from the Curcuma longa
plant. Dietary supplements and foods containing
turmeric are widely promoted for relief of pain
and to improve joint mobility, immunity, digestion,
cardiovascular health, depression, anxiety, memory,
and cognition.
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
) (POD1UM-201). J ImmunoTher Cancer 2021; 9(Suppl
2):A574. 3. Approximate WAC or manufacturer’s published ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA for
treatment of metastatic or recurrent locally advanced
Merkel cell carcinoma (MCC) in adults. Accelerated
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third
drug to be approved in the US for treatment of MCC;
pembrolizumab (Keytruda), a PD-1 blocking antibody,
is approved for the same indication as retifanlimab
in patients ≥12 years old and avelumab (Bavencio),
a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4 doi:10.58347/tml.2023.1674h | Show Introduction Hide Introduction